These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 14584722)

  • 1. Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics.
    Li Z; Meredith MP
    J Biopharm Stat; 2003 Nov; 13(4):777-92. PubMed ID: 14584722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses.
    Delmas PD; Li Z; Cooper C
    J Bone Miner Res; 2004 Feb; 19(2):330-7. PubMed ID: 14969404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of continuous outcome data from individual patients.
    Higgins JP; Whitehead A; Turner RM; Omar RZ; Thompson SG
    Stat Med; 2001 Aug; 20(15):2219-41. PubMed ID: 11468761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect.
    Teramukai S; Matsuyama Y; Mizuno S; Sakamoto J
    Jpn J Clin Oncol; 2004 Dec; 34(12):717-21. PubMed ID: 15640501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the impact of attrition in randomized controlled trials.
    Hewitt CE; Kumaravel B; Dumville JC; Torgerson DJ;
    J Clin Epidemiol; 2010 Nov; 63(11):1264-70. PubMed ID: 20573482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decade of trials of interferon-alpha for chronic hepatitis C. A meta-regression analysis.
    Tinè F; Attanasio M; Russo F; Pagliaro L
    Contemp Clin Trials; 2005 Apr; 26(2):179-210. PubMed ID: 15837440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
    Buyse M
    Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple-outcome meta-analysis of clinical trials.
    Berkey CS; Anderson JJ; Hoaglin DC
    Stat Med; 1996 Mar; 15(5):537-57. PubMed ID: 8668877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors.
    Schmid CH; Stark PC; Berlin JA; Landais P; Lau J
    J Clin Epidemiol; 2004 Jul; 57(7):683-97. PubMed ID: 15358396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials.
    Jones AP; Riley RD; Williamson PR; Whitehead A
    Clin Trials; 2009 Feb; 6(1):16-27. PubMed ID: 19254930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of continuous outcomes combining individual patient data and aggregate data.
    Riley RD; Lambert PC; Staessen JA; Wang J; Gueyffier F; Thijs L; Boutitie F
    Stat Med; 2008 May; 27(11):1870-93. PubMed ID: 18069721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empirical comparison of subgroup effects in conventional and individual patient data meta-analyses.
    Koopman L; van der Heijden GJ; Hoes AW; Grobbee DE; Rovers MM
    Int J Technol Assess Health Care; 2008; 24(3):358-61. PubMed ID: 18601805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes.
    Smith CT; Williamson PR; Marson AG
    J Eval Clin Pract; 2005 Oct; 11(5):468-78. PubMed ID: 16164588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new and rapid scoring system to assess the scientific evidence from clinical trials.
    Silber S
    J Interv Cardiol; 2006 Dec; 19(6):485-92. PubMed ID: 17107362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should meta-regression analyses be undertaken and interpreted?
    Thompson SG; Higgins JP
    Stat Med; 2002 Jun; 21(11):1559-73. PubMed ID: 12111920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining summaries of binary outcomes with those of continuous outcomes in a meta-analysis.
    Whitehead A; Bailey AJ; Elbourne D
    J Biopharm Stat; 1999 Mar; 9(1):1-16. PubMed ID: 10091907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Meta-analyses on individual patient data and treatment evaluation in oncology].
    Pignon JP; Aupérin A; Hill C
    Bull Cancer; 2007 Nov; 94(11):957-64. PubMed ID: 18055313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating patient exclusion bias in meta-analysis.
    Tierney JF; Stewart LA
    Int J Epidemiol; 2005 Feb; 34(1):79-87. PubMed ID: 15561753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining multiple outcome measures in a meta-analysis: an application.
    Arends LR; Vokó Z; Stijnen T
    Stat Med; 2003 Apr; 22(8):1335-53. PubMed ID: 12687658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.